Stembio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Stembio General Information

Description

Operator of a healthcare company based in Seoul, South Korea. The company specializes in colorectal cancer monoclonal antibodies, providing patients with anticancer drugs that target novel prion proteins.

Contact Information

Website
www.stembio.co.kr
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Entrepreneur Hall, 3rd floor, 22 Suncheonhyang-ro, Sinchang-myeon
  • Asan, Chungcheongnam
  • South Korea
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Entrepreneur Hall, 3rd floor, 22 Suncheonhyang-ro, Sinchang-myeon
  • Asan, Chungcheongnam
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Stembio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Aug-2023 Completed Out of Business
2. Accelerator/Incubator 18-Oct-2022 Completed Startup
1. Seed Round Completed Startup
To view Stembio’s complete valuation and funding history, request access »

Stembio Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Stembio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023146035-A1 Novel antibody having excellent binding strength with respect to human prion proteins, and use thereof Inactive 28-Jan-2022
WO-2023090553-A1 Diagnostic kit for diagnosing colorectal cancer using human urine as sample Inactive 18-Nov-2021
WO-2023022473-A1 Composition comprising stem cell-derived extracellular vesicle as active ingredient Inactive 17-Aug-2021
WO-2022215925-A1 Composition for promoting osteogenesis, comprising milk-derived extracellular vesicles Inactive 07-Apr-2021
US-20210361715-A1 Use of exosome derived from mesenchymal stem cells co-cultured with melatonin in prevention and treatment of chronic kidney disease Inactive 21-May-2020 A61P13/12
To view Stembio’s complete patent history, request access »

Ready to get started?

Request a free trial

Stembio FAQs

  • When was Stembio founded?

    Stembio was founded in 2019.

  • Where is Stembio headquartered?

    Stembio is headquartered in Asan, South Korea.

  • What industry is Stembio in?

    Stembio’s primary industry is Biotechnology.

  • Is Stembio a private or public company?

    Stembio is a Private company.

  • What is Stembio’s current revenue?

    The current revenue for Stembio is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process